GeneDx Holdings Corp. Class A (WGS)

In the past six months, GeneDx Holdings Corp.'s stock price has been impacted by several events. In January 2026, the stock fell by 14% after the company's 2026 revenue guidance disappointed investors, despite strong preliminary 2025 results. Positive developments include a strategic partnership with Komodo Health and the announcement of GenomeDx Prenatal™ in January 2026. Insider selling has also been noted, with the CFO and a director selling shares in December 2025.

A historical seasonal timeframe for GeneDx Holdings Corp. from December 10 to March 1 has shown positive results, outperforming the S&P 500 Total Return Index in three out of four periods. The endorsement by the American Academy of Pediatrics (AAP) recommending exome and genome sequencing as first-tier tests for children with developmental delays or intellectual disabilities is anticipated to drive sustained demand for GeneDx's services starting in 2026.

GeneDx Holdings Corp. is a genomics company specializing in genetic testing services, primarily focusing on pediatric and rare disease diagnostics. The company operates within the Healthcare sector, specifically in the Health Care Services and Diagnostics & Research industries. GeneDx's major products and services include whole exome and genome sequencing, offered through its ExomeDx™ and GenomeDx™ tests, which have received FDA Breakthrough Device designation. They also recently expanded into prenatal care with GenomeDx Prenatal™. The company leverages an AI-based platform for next-generation sequencing (NGS) analysis, interpretation, and clinical reporting for rare diseases, hereditary risks, and cancer testing, alongside providing data and information services. GeneDx is recognized as a global leader in rare disease diagnosis, aiming to integrate genomics as a primary tool in healthcare.

GeneDx Holdings Corp. is headquartered in Stamford, Connecticut, United States. The company serves healthcare providers, academic institutions, and pharmaceutical companies both across the United States and internationally.

GeneDx holds a "Moderate Buy" consensus rating from ten brokerages, with an average 12-month price target of $138.13. The company's reputation is bolstered by its position as a global leader in rare disease diagnosis and its FDA Breakthrough Device designation for its core tests. Strategic partnerships and the expansion of its product offerings further enhance its standing in the genomic medicine field.

GeneDx Holdings Corp. has significant institutional ownership, with 61.72% to 105.13% of its stock held by institutional investors. Major institutional owners include Corvex Management LP, Casdin Capital LLC, BlackRock, Inc., William Blair Investment Management LLC, Vanguard Group Inc., Goldman Sachs Group Inc., Oracle Investment Management Inc., Summit Partners Public Asset Management LLC, T. Rowe Price Investment Management, Inc., and Franklin Resources Inc. Individual insiders own approximately 1.25% to 29.60% of the company's stock, with Eli Casdin being the largest individual shareholder.